Regional Morning Notes

COMPANY UPDATE

Li Ning Company (2331 HK)

Leading In The Revival Of Domestic Sports Brands

We believe sportswear demand has been delayed by the spreading pandemic. Li Ning maintained its guidance of a high-teen to low-twenties sales growth in 2022. We believe Li Ning is leading in the revival of domestic sports brands. Its high-quality products backed by rising R&D abilities and high operational efficiency would continue to drive earnings growth ahead. Maintain BUY with a target price of HK\$96.00.

WHAT'S NEW

- New store opening plan in 2022. Li Ning Company (Li Ning) plans to open ~250 Li Ning mass product stores, 150-200 Li Ning Young stores, 10-20 Li Ning 1990 stores, and dozens (vs 93 in 2021) of China Li Ning stores in 2022. Moreover, it will open 300-400 (vs ~400 in 2021) large-sized (>300sqm) stores with high operational efficiency in 2022, which will be mainly in the shopping malls. It will continue to open the large-sized and high-efficient stores in the future.
- Demand exists despite pandemic. Despite the continued spread of the pandemic, Li Ning sees a relatively stable supply chain nationwide as the goods for April and May have already arrived for most of the stores while the goods for June have arrived for some stores. Unlike restaurant operations, we believe demand for sportswear would remain solid and be only delayed by the spreading pandemic.

STOCK IMPACT

- Best representative in revival of domestic sports brands. Thanks to the fashion show held on the Tmall China Day during the New York Fashion Week in Feb 18, China Li Ning became the pioneer of the revival of domestic sports brands. We believe that: a) the company's abundant top-tier sports resources (eg China national sports teams, Wade), and b) its ability to expand crossover resources (eg Dunhuang Fashion week in the desert in Aug 20, and Fashion Music Festival in Dec 21) would allow the Li Ning brand to reach diverse segments of consumers and enlarge its customer base. Hence, this would strengthen brand recognition of Li Ning and its leading position among domestic sports brands.
- Increasing R&D competence. Beng (龗) technology can offer 80% energy feedback, and Jiang (彁) technology can provide a quick rebound and the protection to body joints during running. The two technologies are considered to be the first-class globally. Li Ning plans to expand the usage of Beng technology to mid-to-low tier running shoes, and other segments' products (eg basketball and training) in 2022. Its R&D cost saw a 24.6% 4-year CAGR in 2017-21, indicating the company's efforts in manufacturing high-quality products. We believe Li Ning's products would gain further recognition from customers and become more popular in the future.

KEY FINANCIALS

Year to 31 Dec (HK\$m)	2020	2021	2022F	2023F	2024F
Net turnover	14,457	22,572	26,830	32,731	39,609
EBITDA	2,838	5,841	6,692	8,206	10,203
Operating profit	1,834	4,736	5,534	6,990	8,922
Net profit (rep./act.)	1,698	4,011	4,700	5,849	7,370
Net profit (adj.)	1,698	4,011	4,700	5,849	7,370
EPS (sen)	67.6	158.0	185.1	230.4	290.3
PE (x)	72.6	31.1	26.5	21.3	16.9
Р/В (х)	14.1	6.1	5.2	4.4	3.7
EV/EBITDA (x)	39.9	19.4	16.9	13.8	11.1
Dividend yield (%)	0.4	0.9	1.1	1.4	1.7
Net margin (%)	11.7	17.8	17.5	17.9	18.6
Net debt/(cash) to equity (%)	(69.9)	(63.3)	(62.1)	(63.0)	(60.8)
Interest cover (x)	89.8	n.a.	n.a.	n.a.	n.a.
ROE (%)	21.5	26.9	20.6	21.8	23.1
Consensus net profit	-		4,768	5,921	7,326
UOBKH/Consensus (x)	-		0.99	0.99	1.01

Source: Li Ning, Bloomberg, UOB Kay Hian

BUY

(Maintained)

Share Price	HK\$60.45
Target Price	HK\$96.00
Upside	+58.8%
(Previous TP:	HK\$113.42)

COMPANY DESCRIPTION

Li Ning is one of the leading sportswear companies in China. It has the main brand Li Ning and other sub-brands, including China Li Ning, Li Ning Young, Li Ning 1990.

STOCK DATA

GICS sector	Consumer Discretionary
Bloomberg ticker:	2331 HK
Shares issued (m):	2,616.8
Market cap (HK\$\$m):	158,188.3
Market cap (US\$m):	20,182.2
3-mth avg daily t'over	(US\$m): 165.5
Price Performance (%)
52-week high/low	HK\$107.70/HK\$50.95

52-week high/low		HK\$107.70/HK\$50.95		
1mth	3mth	6mth	1yr	YTD
(10.9)	(20.4)	(25.3)	9.1	(29.2)
Major Sh	nareholders		%	
Viva China Holdings Limited				10.36
	//Oh a /D			0.40
FYZZ NAV	//Share (Rmb		9.40	
FY22 Net Cash/Share (Rmb)				5.83

PRICE CHART



Source: Bloomberg

ANALYST(S)

Shen Zhifeng

+8621 5404 7225 ext.811 zhifeng@uobkayhian.com

Ng Jo Yee

+603 2147 1984 joyee@uobkayhian.com

Regional Morning Notes

- Effective channel restructure. Li Ning started its channel restructure in 2012 and targeted to lift retail sales efficiency and achieve high-quality growth. In recent years, its efforts were mainly focused on: a) opening efficient and large-sized stores in the core cities (especially the Tier 1 & 2 cities), and closing the underperforming or loss-making stores; b) upgrading the decoration of stores that were opened before 2019 to improve consumers' purchase experiences; c) raising the franchised stores' operational efficiency based on experiences gleaned from self-operated stores; d) replicating the standardised operational model of high operational efficiency stores in all other stores. Hence, the proportion of stores in Tier 1 & 2 cities and in Tier 3 & 4 cities increased 10ppt and 3ppt respectively, and the proportion of stores in shopping malls hiked more than 15ppt as of end-21, compared with end-19. Its overall annual per store sales surged more than 60% in 2021, and the large stores' annual per store sales tores. Also, Li Ning will decide the sell-in plan based on the sell-through situations, which we think would lower the risks from high inventory.
- Rising direct sales with strong online sales expansion. The share of sales revenue from franchised distributors continuously dropped to 48.1% in 2021 from 79.0% in 2011. However, its online sales recorded 55.6% 7-year CAGR in 2014-21, accounting for 28.4% of total revenue in 2021 from 4.9% in 2014. The number of online members reached 40m as of end-21, and their sales contributions increased by low-teens in 2021. In addition, the number of low-efficiency online wholesale stores declined by mid-forties in 2021. With Li Ning's effective e-commerce strategies (eg the omni-channel inventory and resources sharing), we believe its online sales would continue to grow fast in the future. The company guided for online sales to grow 20% per year in the next few years.
- Solid sales expansion with multiple drivers. Li Ning achieved a 26.3% 4-year revenue CAGR in 2017-21, and guided for a high-teen to low-twenties top-line growth and a high-teen net profit margin for 2022. It achieved high-thirties to low-forties offline sales growth in some cities before the resurgence of the pandemic in Mar 22. It also expects a mid-single-digit revenue growth in 2Q22 despite the high base in 2Q21. The company stated that Li Ning mass products (offline) would contribute a mid-to-high single-digit in the total revenue growth in 2022, while China Li Ning and Li Ning Young would likely see 40-60% sales growth and a mid-single-digit revenue growth in 2022. With a clear and firm long-term strategy, we expect China LN and LN Young to continue the fast expansion and contribute more in the top line growth in the future.
- Expecting stable gross margins ahead. Although the company guided a 1% drop in gross margin in 2022 given the high material costs, we reckon that Li Ning would likely see a margin recovery after 2022 thanks to its brand elevation and high operational efficiency. The potential improvement in new products' sell-out rate, retail discount rate, and the delivery discount and rebate rate to distributors would improve gross margin.
- Stable supply chain. Li Ning's production capacity hiked 50% in 2021. It is lifting the share of orders to the core suppliers. Its top three suppliers' capacity accounted for 45% of total capacity as of end-21. We think the top suppliers would facilitate flexible production for Li Ning. Li Ning has also planned its logistics in the next 3-5 years to further lift its operational efficiency and customers' purchase experiences.

EARNINGS REVISION/RISK

- Earnings forecasts. We estimate 17.2%/24.4%/26.0% earnings growth for 2022/23/24.
- Risks. a) Continuous spread of pandemic, b) costs of materials remaining high.

VALUATION/RECOMMENDATION

• Maintain BUY with a target price of HK\$96.00. We believe Li Ning brand is the leader in the revival of domestic sportswear brands. Its increasing R&D capabilities and operational efficiency would further strengthen Li Ning's brand power in customers' minds. Maintain BUY. Our target price implies 45.5x 2022F PE and 36.6x 2023F PE.

Monday, 11 April 2022

Regional Morning Notes

Monday, 11 April 2022

PROFIT & LOSS

Year to 31 Dec (Rmbm)	2021	2022F	2023F	2024F
Net turnover	22,572.3	26,830.3	32,730.7	39,608.8
EBITDA	5,840.6	6,691.8	8,206.4	10,203.2
Deprec. & amort.	1,104.6	1,157.9	1,216.5	1,281.0
EBIT	4,736.0	5,533.9	6,989.8	8,922.1
Total other non-operating income	326.3	326.3	326.3	326.3
Associate contributions	159.2	170.0	172.0	175.0
Net interest income/(expense)	32.6	133.4	187.1	249.1
Pre-tax profit	5,328.2	6,163.6	7,675.3	9,672.5
Тах	(1,317.3)	(1,463.9)	(1,826.7)	(2,302.1)
Minorities	0.0	0.0	0.0	0.0
Net profit	4,010.9	4,699.8	5,848.6	7,370.5
Net profit (adj.)	4,010.9	4,699.8	5,848.6	7,370.5

BALANCE SHEET				
Year to 31 Dec (Rmbm)	2021	2022F	2023F	2024F
Fixed assets	1,625.9	1,692.0	1,758.1	1,824.2
Other LT assets	9,977.1	10,108.8	10,253.9	10,413.6
Cash/ST investment	14,744.9	16,660.1	19,698.6	22,471.0
Other current assets	3,927.0	6,116.8	7,291.7	10,304.1
Total assets	30,274.8	34,577.7	39,002.3	45,012.8
ST debt	417.1	417.1	417.1	417.1
Other current liabilities	7,286.8	8,093.1	8,079.1	8,473.8
LT debt	977.5	977.5	977.5	977.5
Other LT liabilities	489.4	489.4	489.4	489.4
Shareholders' equity	21,101.5	24,598.1	29,036.7	34,652.6
Minority interest	2.6	2.6	2.6	2.6
Total liabilities & equity	30,274.8	34,577.7	39,002.3	45,012.8

CASH FLOW

Year to 31 Dec (Rmbm)	2021	2022F	2023F	2024F
Operating	4,707.6	3,754.5	5,084.4	5,162.9
Pre-tax profit	5,328.2	6,163.6	7,675.3	9,672.5
Тах	(1,317.3)	(1,463.9)	(1,826.7)	(2,302.1)
Deprec. & amort.	571.5	571.5	571.5	571.5
Working capital changes	558.0	(1,383.5)	(1,189.0)	(2,617.7)
Non-cash items	(266.8)	(133.3)	(146.6)	(161.3)
Other operating cashflows	(166.0)	0.0	0.0	0.0
Investing	3,085.9	(636.0)	(636.0)	(636.0)
Capex (growth)	(1,094.7)	(600.0)	(600.0)	(600.0)
Investments	(30.7)	(36.0)	(36.0)	(36.0)
Proceeds from sale of assets	0.0	0.0	0.0	0.0
Others	4,211.3	0.0	0.0	0.0
Financing	(235.6)	(1,203.3)	(1,409.9)	(1,754.6)
Dividend payments	(509.5)	(1,203.3)	(1,409.9)	(1,754.6)
Issue of shares	0.0	0.0	0.0	0.0
Proceeds from borrowings	0.0	0.0	0.0	0.0
Loan repayment	0.0	0.0	0.0	0.0
Others/interest paid	273.9	0.0	0.0	0.0
Net cash inflow (outflow)	7,557.9	1,915.2	3,038.5	2,772.4
Beginning cash & cash equivalent	7,187.0	14,744.9	16,660.1	19,698.6
Changes due to forex impact	0.0	0.0	0.0	0.0
Ending cash & cash equivalent	14,744.9	16,660.1	19,698.6	22,471.0

KEY METRICS

Year to 31 Dec (%)	2021	2022F	2023F	2024F
Profitability				
EBITDA margin	25.9	24.9	25.1	25.8
Pre-tax margin	23.6	23.0	23.4	24.4
Net margin	17.8	17.5	17.9	18.6
ROA	17.9	14.5	15.9	17.5
ROE	26.9	20.6	21.8	23.1
Growth				
Turnover	56.1	18.9	22.0	21.0
EBITDA	105.8	14.6	22.6	24.3
Pre-tax profit	137.0	15.7	24.5	26.0
Net profit	136.1	17.2	24.4	26.0
Net profit (adj.)	136.1	17.2	24.4	26.0
EPS	133.6	17.2	24.4	26.0
Leverage				
Debt to total capital	6.2	5.4	4.6	3.9
Debt to equity	6.6	5.7	4.8	4.0
Net debt/(cash) to equity	(63.3)	(62.1)	(63.0)	(60.8)
Interest cover (x)	n.a.	n.a.	n.a.	n.a.

Regional Morning Notes

Monday, 11 April 2022

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered brokerdealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Regional Morning Notes

Monday, 11 April 2022

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or
	located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to
	applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed
	corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong
	Kong and contains research analyses or reports from a foreign research house, please note:
	(i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong
	Kong in respect of any matters arising from, or in connection with, the analysis or report; and
	(ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong
	who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority
	of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a
	foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant
	foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the
	recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia,
	at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the
0:	registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the
	report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note:
	(i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore
	in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore
	who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the
	contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated
	by the Securities and Exchange Commission of Thailand.
United	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning
Kingdom	of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in
-	the UK is intended only for institutional clients.
United	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S.
States of	laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its
America	contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in
('U.S.')	the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2022, UOB Kay Hian Pte Ltd. All rights reserved.

http://research.uobkayhian.com

RCB Regn. No. 197000447W